Genotoxicity Genotype Marketing Medicine 
The Pharma Data
MARCH 25, 2021
The validation of our EU marketing application is an important step toward addressing the significant unmet medical need for people with metastatic triple-negative breast cancer.”. Canada, Switzerland and Australia, as well as in Singapore through our partner Everest Medicines. Gilead Sciences, Inc. About the ASCENT Study.
The Pharma Data
APRIL 7, 2021
“Women with triple-negative breast cancer have historically had very few effective treatment options and faced a poor prognosis,” said Aditya Bardia, MD, MPH, Director of Breast Cancer Research Program, Mass General Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and global principal investigator of the ASCENT study.
Expert insights. Personalized for you.
52 
Let's personalize your content